Last updated: July 21, 2026
Litigation summary and analysis for Radius Health, Inc. v. Orbicular Pharmaceutical Technologies Private Limited (D. Mass. 1:22-cv-11546)
Radius Health, Inc. sued Orbicular Pharmaceutical Technologies Private Limited in the District of Massachusetts for patent infringement under the Hatch-Waxman framework in case number 1:22-cv-11546. The docket information necessary to produce an accurate infringement-and-procedure summary (asserted patents, Orange Book ties, Paragraph IV framework, claim construction, motions, and settlement or trial status) is not provided.
If the full case record is available, this case can be analyzed along five lines: (1) which asserted U.S. patents map to which FDA-listed product(s), (2) whether the case is tied to an ANDA Paragraph IV certification and what “automatic” stay risk exists, (3) the procedural posture through claim construction and dispositive motion practice, (4) infringement and invalidity theories used by both sides, and (5) whether any settlement terms or final orders affect generic entry timing.
What is the case’s core legal posture and what does it typically target?
Direct answer: Hatch-Waxman patent infringement cases like this typically target FDA ANDA approval tied to an Orange Book-listed brand drug, using allegations that the generic product infringes one or more asserted claims of listed patents.
What patents were asserted in 1:22-cv-11546?
Direct answer: Not determinable from the information supplied.
Which Orange Book patents usually get asserted in Radius Health cases?
Direct answer: Not determinable from the information supplied. (Radius Health’s product portfolio often implicates bone health and related therapies; however, the specific asserted patent list for this docket is required to avoid misstatement.)
Did the case involve a Paragraph IV certification and what are the exclusivity/stay implications?
Direct answer: Not determinable from the information supplied.
How Paragraph IV timing drives launch risk in generic cases
Direct answer: In a typical ANDA Paragraph IV scenario:
- 30-month stay runs from FDA’s patent certification notice date (subject to triggers and injunctions).
- Litigation outcomes drive whether a court-ordered finding of noninfringement/invalidity allows earlier FDA approval and launch.
What procedural milestones occurred (motions, claim construction, hearings, trial)?
Direct answer: Not determinable from the information supplied.
What filings matter for litigation analysis
A complete analysis requires:
- complaint filing date and asserted patent numbers
- answer and affirmative defenses (including inequitable conduct, noninfringement, invalidity bases)
- scheduling order and Markman/claim construction dates
- summary judgment orders
- preliminary injunction status (if any)
- status conferences, PTO-related stay orders, or voluntary dismissal
How strong is the infringement and validity posture for each side?
Direct answer: Not determinable from the information supplied.
What “strength” typically depends on in these cases
- Claim scope and claim construction outcomes
- Prior art invalidity landscape (obviousness, anticipation, written description/enablement)
- Prosecution history estoppel and doctrine-based limitations
- Product-specific mapping (ANDA formulation, label, manufacturing method, or proposed use)
Settlement or final disposition: did the parties resolve the dispute?
Direct answer: Not determinable from the information supplied.
What to look for if the case settled
A reliable settlement analysis requires:
- date and terms summary (typically launch date, design-around commitments, covenant-not-to-sue)
- whether settlement includes dismissal with prejudice or consent judgment
- any negotiated “skinny label” or carve-out changes
What generic entry risks exist for Orbicular’s ANDA pathway?
Direct answer: Not determinable from the information supplied.
What an entry risk assessment must include
- whether the court found any asserted claims invalid or not infringed
- whether injunctions were issued
- whether FDA approval is blocked by remaining asserted patents
- whether any pediatric exclusivity or other regulatory exclusivity still bars approval
Key Takeaways
- The case is identified as Radius Health, Inc. v. Orbicular Pharmaceutical Technologies Private Limited, D. Mass., 1:22-cv-11546.
- A litigation summary and infringement/validity analysis cannot be completed accurately without the docket record content (asserted patents, Orange Book linkage, and procedural history).
- Once the docket details are available, a high-fidelity analysis can be produced covering Paragraph IV posture, asserted patent estate, claim construction and dispositive motion outcomes, and downstream launch timing impacts.
FAQs
- What is the typical Hatch-Waxman process for a brand company suing an ANDA filer in the District of Massachusetts?
- How do claim construction results usually affect settlement leverage in pharmaceutical patent cases?
- What factors determine whether a 30-month stay remains in force after key court rulings?
- How do design-around strategies and “carve-out” labels reduce infringement risk against method-of-use or formulation claims?
- What court orders most directly control generic launch timing after litigation in an ANDA Paragraph IV case?
References
- No source documents were provided in the prompt sufficient to cite the docket, complaint, or orders for this case.
